Genmab A/S
GMAB----
Genmab A/S (GMAB)
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The comp...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Genmab A/S Analyst Rating
View MoreForecast & Rating
Jul 22, 2026Price forecast
$37.9631.49%
Forecast & RatingStrong buy
11analysts
- Strong buy90.91%
- Buy0.00%
- Hold9.09%
- Sell0.00%
- Strong sell0.00%
News
- MorningStar · 23 hours ago
Stocks to Watch: Intel, Deckers, Edwards Lifesciences, Genmab
- PUBT · 1 day ago, 03:00 PM
Genmab, AbbVie clarify primary endpoints in Phase 3 EPCORE DLBCL-1 trial
- Tip Ranks · 1 day ago, 07:57 AM
Genmab (GMAB) Receives a Hold from Morgan Stanley
- PUBT · Jul 15 at 05:27 AM
Genmab says Q2 2026 DARZALEX net sales total USD 4.21 billion
- Tip Ranks · Jul 12 at 07:15 AM
Jefferies Keeps Their Buy Rating on Genmab A/S (0MGB)
- rttnews · Jul 10 at 11:15 AM
Weekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goal
